Abstract 9941: Valvulitis Masquerading as Culture Negative Endocarditis in an Immunosuppressed Patient A Case Report
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.9941 ↗Kurz gefasst
Fallbericht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Tushar Ralhan und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction: Blood culture-negative endocarditis (BCNE) accounts for up to 31% of infective endocarditis (IE) cases. In immunosuppressed patients with rheumatic heart disease (RHD), inflammatory valve pathology can mimic IE on echocardiography, creating diagnostic uncertainty with therapeutic consequences. Patient Information: A 49-year-old woman with seropositive rheumatoid arthritis on abatacept and leflunomide, hypertension, diabetes, obesity, right nephrectomy for renal-cell carcinoma, and left thalamic stroke presented with dyspnea, orthopnea, leg edema, night sweats, and fatigue without fever. Clinical Findings and Timeline: Examination revealed pitting edema, RUQ tenderness, severe tricuspid regurgitation, moderate mitral/aortic regurgitation, and no endocarditis findings. Transesophageal echocardiography (TEE) showed severe rheumatic mitral stenosis/regurgitation with restricted posterior leaflet and 1-cm anterior mitral leaflet echodensity. ESR 61 mm/h, CRP 2.4 mg/dL, NT-proBNP 6,000 pg/mL without leukocytosis. Blood cultures x3 (fungal, mycobacterial) negative at 96 hours; Bartonella, Brucella, Coxiella, Tropheryma whipplei, and antiphospholipid antibodies were negative. CT head: multifocal subacute strokes; CT abdomen: old splenic infarct. Right-heart catheterization confirmed severe pulmonary hypertension (PAP 57, PCWP 44 mmHg). Diagnostic Assessment and Reasoning: Differential: BCNE, nonbacterial thrombotic endocarditis, Libman-Sacks endocarditis, and rheumatic valvulitis exacerbation. The echodensity and multiterritory embolic events in an immunosuppressed host raised concern for IE; negative cultures and RHD suggested noninfective etiologies. 18F-FDG PET/CT was not performed due to hemodynamic instability. Therapeutic Interventions: Empiric ceftriaxone and vancomycin were stopped after 5 days given negative cultures and nephrotoxicity risk (solitary kidney). Antirheumatic drugs held. Mitral valve replacement and tricuspid repair followed team discussion. Follow-Up, Outcomes, and Adverse Events: Histopathology showed acute and chronic inflammation, myxoid degeneration, and microcalcifications without organisms or microabscesses, confirming rheumatic valvulitis with superimposed inflammation. Postoperative cardiogenic shock required VA-ECMO; the patient died. Discussion and Synthesis: The 2023 Duke-ISCVID criteria improved IE diagnostic sensitivity (84% vs. 75%) by incorporating PET/CT; however, PET/CT has limited sensitivity for native valve IE (as low as 22%) and may yield false-positive uptake in inflammatory valve disease. Surgical pathology served as the definitive diagnostic discriminator. Clinicians should recognize that not all mobile valve lesions with embolic events represent infection, and tissue diagnosis remains essential when noninvasive criteria are inconclusive.
Zitieren
APA
Ralhan, T., Patel, H., Moheet, S., Huq, S., Cortes, E. B., & Modi, J. (2026). Abstract 9941: Valvulitis Masquerading as Culture Negative Endocarditis in an Immunosuppressed Patient A Case Report. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.9941
Vancouver
Ralhan T, Patel H, Moheet S, Huq S, Cortes EB, Modi J. Abstract 9941: Valvulitis Masquerading as Culture Negative Endocarditis in an Immunosuppressed Patient A Case Report. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.9941
BibTeX
@article{Ralhan2026,
author = {Ralhan, Tushar and Patel, Hardik and Moheet, Shaan and Huq, Shahana and Cortes, Edgar Betancourt and Modi, Jhalak},
title = {Abstract 9941: Valvulitis Masquerading as Culture Negative Endocarditis in an Immunosuppressed Patient A Case Report},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.9941}
}
EUVIMED